

Please complete the form, sign, and FAX to 1-844-237-3172. For assistance, please call 1-844-468-2252 Monday – Friday, 8AM to 8PM ET.

## Important instructions for completing the Gateway to Nucala Enrollment Form

### Step 1: Patient Information (Page 2)

- ← Complete the Patient Information section
- ← Complete the Insurance Information section
- ← If requesting Patient Assistance Program, have the patient complete this section

### Step 2: Prescriber Information (Page 3)

- ← Complete the Prescriber Information section
- ← If place of care administration differs from the prescribing office, complete the Site of Care section
- ← Complete the Diagnosis Codes and Clinical Information Section

### Step 3: Prescription Information (Page 4)

- ← Complete the Prescription Information section
- ← If Bridge is requested, Bridge to NUCALA section
- ← Complete Prescriber Signature

### Step 4: Patient Consent and Signature (Page 2)

- ← Return to Page 2 and obtain the patient's signature. Please note:
  - HIPAA Signature is required
  - MyNUCALA signature is optional

### Next Steps



Provide a signed copy of this form to the patient



Fax completed enrollment form to 1-844-237-3172 or submit electronically to Gateway for Nucala at [www.GatewaytoNucala.com](http://www.GatewaytoNucala.com)

**This page intentionally left blank**

# ENROLLMENT FORM

# Gateway to Nucala

Please complete the form, sign, and FAX to 1-844-237-3172. For assistance, please call 1-844-468-2252 Monday – Friday, 8AM to 8PM ET.

## Gateway to Nucala Services

- Benefits Verification and Prior Authorization Research
- Prior Authorization Follow-up and Appeal Support
- Co-pay Program (**commercial only**)
- Patient Assistance Program (PAP)

- Specialty Pharmacy (SP) Triage
- Claims and Billing Support
- Bridge to NUCALA (complete Bridge Rx on page 4)

MyNUCALA Support (Optional): Disease-specific education, patient support services, and other communication

## Patient Information \*Indicates required fields

Last name*:		First name*:	
Street*:		City*:	
State*:	Zip*:	Email:	
Date of birth* (mm/dd/yyyy):	Gender:	Language preference (if other than English):	
Preferred phone #*:	<input type="checkbox"/> Home <input type="checkbox"/> Mobile	Alternate contact name:	
OK to leave a detailed voicemail? <input type="checkbox"/> Yes <input type="checkbox"/> No		Home/Mobile:	
Preferred time to call: <input type="checkbox"/> Morning <input type="checkbox"/> Afternoon <input type="checkbox"/> Evening		Alternate contact phone:	
		Alternate contact relationship to patient:	

<b>Enroll in Mobile Text Notifications (Optional):</b> <input type="checkbox"/> Opt-in (include mobile phone number above)	By opting into texting you authorize GSK and its service providers to contact you and send communications about your enrollment in Gateway to NUCALA via telephone and text message. These calls or text messages may be generated using auto-dial or pre-recorded messages at the number you submit. The number and type of messages will be based upon your program selections, and message and data rates may apply. At any time, you may request to stop telephone calls or text messages by following the opt-out directions provided during those communications.
---	---

Print name:	Relationship to patient:
-------------	--------------------------

<b>GATEWAY PATIENT AUTHORIZATION*</b>	<b>PATIENT SIGNATURE REQUIRED HERE</b>	Date:
---------------------------------------	--	-------

I have read and agree to the HIPAA Patient Authorization form (please see page 6).\*

<b>MYNUCALA SUPPORT CONSENT</b>	<b>PATIENT SIGNATURE HERE</b>	Date:
---------------------------------	-------------------------------	-------

I have read and agree to the OPTIONAL MyNUCALA Support consent (please see page 5).  
If you have chosen to participate in the MyNUCALA Program, please fill in your email on page 5.

## \*Insurance Information: Please provide front and back copies of all medical and prescription insurance cards

<input type="checkbox"/> No insurance	Primary insurance	Secondary insurance	Pharmacy insurance
Insurance provider			
Insurance phone			
Cardholder name (if not the patient)			
Cardholder DOB			
Policy #			
Group #			
BIN/PCN	N/A	N/A	

## Patient Assistance Program (PAP): Patient to complete only if requesting PAP

Uninsured and eligible Medicare patients who are prescribed NUCALA may be eligible for the GSK Patient Assistance Program (PAP). To find out if you qualify, please fill in the information below.

Annual pretax household income:	Number of family members living in household:	<b>PATIENT TO COMPLETE</b>
Medicare Beneficiary Identifier (MBI):		

Applicants authorize the GSK Specialty PAP and its administrators to obtain a consumer report. The consumer report, and the information derived from public and other sources, will be used to estimate income as part of the process to decide eligibility to receive free medication from the GSK Specialty PAP. Upon request, the GSK Specialty PAP will provide applicants with the name and address of the consumer reporting agency that provides the consumer report. The program may request additional documents and information at any time, even after enrollment, to determine if the information on the enrollment form is complete and true. For additional questions about eligibility, please contact the Gateway to NUCALA.

Trademarks are owned by or licensed to the GSK group of companies.



©2023 GSK or licensor.  
MPLBROC230001 March 2023  
Produced in USA. 0002-0023-51

# ENROLLMENT FORM

Please complete the form, sign, and FAX to 1-844-237-3172. For assistance, please call 1-844-468-2252 Monday – Friday, 8AM to 8PM ET.

## Prescriber, Acquisition, and Administration Information: Prescriber signature required on all enrollment forms

\*Indicates required fields

Prescriber's last name*:	Prescriber's first name*:
Practice name*:	Specialty:
Street*:	
City*:	State*:
Office contact name*:	Phone*:
Prescriber Tax ID*:	State license #*:
Prescriber NPI #*:	

Product Formulation*	Administration Site	Acquisition Method
<input type="checkbox"/> Lyophilized vial (LYO)	→ Office administered only	→ Buy & Bill → Specialty Pharmacy
<input type="checkbox"/> Autoinjector (AI)	→ Patient administered	→ Specialty Pharmacy
<input type="checkbox"/> Prefilled Syringe (PFS)	→ Patient administered	→ Specialty Pharmacy
<input type="checkbox"/> I would like to understand coverage for all formulations.		

## Site of Care: Complete this section ONLY if the place of administration differs from the prescribing office

Administering practice/facility:	Administering physician name:
Street address:	City:
Phone:	State:
Ext:	Zip:
Fax:	NPI:

Check here if Gateway support is needed to identify an appropriate Site of Care (infusion center)

## Diagnosis Codes\* and Clinical Information: It is up to the provider to determine the most appropriate diagnosis code. Consult the patient's payer for coding or documentation requirements.

Severe Asthma	<input type="checkbox"/>	J45.50	Severe persistent asthma, uncomplicated	Eosinophilic Granulomatosis with Polyangiitis (EGPA)	<input type="checkbox"/>	M30.1	Polyarteritis with lung involvement [Churg-Strauss]
	<input type="checkbox"/>	J45.51	Severe persistent asthma with (acute) exacerbation		<input type="checkbox"/>		
	<input type="checkbox"/>	J82.83	Eosinophilic asthma		<input type="checkbox"/>		
Nasal Polyps	<input type="checkbox"/>	J33.0	Polyp of the nasal cavity	Hypereosinophilic Syndrome (HES)	<input type="checkbox"/>	D72.110	Idiopathic hypereosinophilic syndrome [IHES]
	<input type="checkbox"/>	J33.1	Polypoid sinus degeneration		<input type="checkbox"/>	D72.111	Lymphocytic variant hypereosinophilic syndrome [LHES]
	<input type="checkbox"/>	J33.8	Other polyp of sinus		<input type="checkbox"/>	D72.119	Hypereosinophilic syndrome [HES], unspecified
	<input type="checkbox"/>	J33.9	Nasal polyps, unspecified	Other	<input type="checkbox"/>		

Date of Diagnosis:

Allergies:

# ENROLLMENT FORM

# Gateway to Nucala

Please complete the form, sign, and FAX to 1-844-237-3172. For assistance, please call 1-844-468-2252 Monday – Friday, 8AM to 8PM ET.

<b>Patient Name:</b>	<b>Date of Birth (mm/dd/yyyy):</b>
----------------------	------------------------------------

• Prescriber signature below is required for Rx and/or enrollment • Specialty Pharmacy selection is subject to health plan requirements

<input type="checkbox"/> New <input type="checkbox"/> Restart <input type="checkbox"/> Continuing	Last treatment date (mm/dd/yyyy): Next treatment date/Date needed by (mm/dd/yyyy):
---	---

Has the prescription already been forwarded to a Specialty Pharmacy?  No  Yes—which one?

Do not triage the prescription to the Specialty Pharmacy

## PRESCRIPTION: Prescriber to indicate preferred dosing regimen of NUCALA

MEDICATION		STRENGTH/Form	QTY	REFILLS	DIRECTIONS FOR ADMINISTRATION
<b>Office Administered</b>					
NUCALA lyophilized vial (LYO)	<input type="checkbox"/>	100 mg of lyophilized powder in a single-dose vial for reconstitution (NDC 0173-0881-01); reconstitute with 1.2 mL of Sterile Water for Injection, USP			<input type="checkbox"/> Pediatric Severe Asthma (Patients aged 6-11 years): <b>40 mg</b> subcutaneous to upper arm, thigh, or abdomen every 4 weeks (LYO & PFS only)
NUCALA prefilled syringe (PFS)	<input type="checkbox"/>	40 mg/0.4 mL solution in a single-dose prefilled syringe (NDC 0173-0904-42)			
<b>Home Administered</b>					
NUCALA Autoinjector (AI)	<input type="checkbox"/>	100 mg/mL solution in a single-dose prefilled autoinjector (NDC 0173-0892-01)			<input type="checkbox"/> Severe Asthma/Nasal Polyps: <b>100 mg</b> subcutaneous to upper arm, thigh, or abdomen every 4 weeks  <input type="checkbox"/> EGPA/HES: <b>300 mg</b> subcutaneous administered as 3 separate 100-mg injections to upper arm, thigh, or abdomen every 4 weeks
NUCALA prefilled syringe (PFS)	<input type="checkbox"/>	100 mg/mL solution in a single-dose prefilled syringe (NDC 0173-0892-42)			
	<input type="checkbox"/>	40 mg/0.4 mL solution in a single-dose prefilled syringe (NDC 0173-0904-42)			

## Bridge to NUCALA: Prescriber to complete only if Bridge is requested



MEDICATION		STRENGTH/Form	REFILLS	DIRECTIONS FOR ADMINISTRATION /QTY
<b>Office Administered</b>				
NUCALA lyophilized vial (LYO)	<input type="checkbox"/>	100 mg of lyophilized powder in a single-dose vial for reconstitution (NDC 0173-0881-01); reconstitute with 1.2 mL of Sterile Water for Injection, USP	1	<input type="checkbox"/> Pediatric Severe Asthma (Patients aged 6-11 years): <b>40 mg</b> subcutaneous to upper arm, thigh, or abdomen every 4 weeks (LYO & PFS only). <b>QTY: 1</b>
NUCALA prefilled syringe (PFS)	<input type="checkbox"/>	40 mg/0.4 mL solution in a single-dose prefilled syringe (NDC 0173-0904-42)	1	
<b>Home Administered</b>				
NUCALA Autoinjector (AI)	<input type="checkbox"/>	100 mg/mL solution in a single-dose prefilled autoinjector (NDC 0173-0892-01)	1	<input type="checkbox"/> Severe Asthma/Nasal Polyps: <b>100 mg</b> subcutaneous to upper arm, thigh, or abdomen every 4 weeks. <b>QTY: 1</b>  <input type="checkbox"/> EGPA/HES: <b>300 mg</b> subcutaneous administered as 3 separate 100-mg injections to upper arm, thigh, or abdomen every 4 weeks. <b>QTY: 3</b>
NUCALA prefilled syringe (PFS)	<input type="checkbox"/>	100 mg/mL solution in a single-dose prefilled syringe (NDC 0173-0892-42)	1	
	<input type="checkbox"/>	40 mg/0.4 mL solution in a single-dose prefilled syringe (NDC 0173-0904-42)	1	

Bridge to NUCALA provides free product for eligible commercially insured patients when the PA request has been pending with the payer in accordance with program rules and when other program eligibility criteria have been satisfied. Providers may not seek reimbursement for any free product provided under this program, and they acknowledge that the program does not include payment for administration fees.


**Prescriber Declaration:** I certify that the information provided above is true and that NUCALA is being prescribed for the patient listed above. I hereby certify that, for any insured patient seeking co-pay assistance under the Co-pay Program, in the absence of financial support from such program, any applicable co-pay, coinsurance, or other out-of-pocket cost for NUCALA would be collected from the patient upon treatment. I appoint the Gateway to NUCALA, on my behalf, to convey this prescription to the dispensing pharmacy, to the extent permitted under state law. **Special Note:** Prescribers in all states must follow applicable laws for a valid prescription. For prescribers in states with official prescription form requirements, please submit an actual prescription along with this enrollment form. Prescribers may need to submit an electronic prescription to the Specialty Pharmacy.

<b>PRESCRIBER TO SIGN</b>	<b>PRESCRIBER SIGNATURE HERE</b>	
<b>SUBSTITUTION PERMITTED</b>	(Date)	<b>DISPENSE AS WRITTEN*</b>
		(Date)

## What happens next?

<h3>1.</h3>	<p><b>We contact your insurance</b></p> <p>We will investigate your benefits and help you understand your coverage options for NUCALA. Typically, it takes about two business days for application processing.</p>	
<h3>2.</h3>	<p><b>We will contact you</b></p> <p>A representative will call you to help you understand your plan's current coverage, out-of-pocket costs, and financial assistance options (if eligible). A summary of this benefit information will be sent to you and your healthcare provider. The information provided by the Gateway is not a guarantee of coverage.</p> <p><b>What's next?</b></p> <p><b>Look out for a phone call.</b> You may not recognize the number, but it could be a call about your prescription.</p> <p><b>Call your doctor.</b> If you don't hear anything within the next two weeks, <b>contact your doctor's office to check on the status of your prescription.</b></p>	

## Optional: MyNUCALA Support

<h3>3.</h3>	<p>MyNUCALA offers patient services to help you begin and continue treatment with NUCALA. If enrolled, a healthcare professional* from the MyNUCALA Nurse Support Line will call you. The Support Line will get you on your way by answering questions you may have about NUCALA.</p> <p><b>Give them a call: 1-844-4-NUCALA (1-844-468-2252)</b></p> <p>*MyNUCALA personnel do not give medical advice. You will be directed to your healthcare provider for any disease, treatment, or referral-related questions.</p> <p><b>MyNUCALA Support Consent:</b></p> <p>By providing your name, address, email address, and other information including your indication below you are giving GSK and companies working for or with GSK permission to contact you for marketing, market research, or advertising purposes, or to invite you to interact with GSK in other ways across multiple channels (eg, mail, email, websites, online advertising, applications, and services), regarding the medical condition(s) in which you have expressed an interest, as well as other health-related information from GSK. GSK will not sell or transfer your name, address, or email address to any other party for their own marketing use.</p> <p>My indication (select all that apply)</p> <ul style="list-style-type: none"> <li><input type="checkbox"/> Severe Asthma</li> <li><input type="checkbox"/> Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)</li> <li><input type="checkbox"/> Eosinophilic Granulomatosis with Polyangiitis (EGPA)</li> <li><input type="checkbox"/> Hypereosinophilic Syndrome (HES)</li> </ul> <p>For additional information about how GSK handles your information, please see our privacy notice at <a href="https://privacy.gsk.com/en-us">https://privacy.gsk.com/en-us</a>.</p> <p>Email address: _____</p> <p>You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a> or call 1-800-FDA-1088.</p>	
-------------	---	--

**Questions? Call 1-844-4-NUCALA (1-844-468-2252).  
Representatives are available Monday - Friday, 8AM to 8PM ET.**

## PATIENT AUTHORIZATION AND RELEASE TO COLLECT, USE, AND DISCLOSE HEALTH INFORMATION

By signing this form, I **agree** to allow my doctors; pharmacies, including my Specialty Pharmacy(ies); and health insurers (collectively “Healthcare Providers”) to use and disclose my health information to GlaxoSmithKline and its agents, authorized representatives, and contractors (collectively “GSK”) so that GSK can use and disclose my health information for purposes of providing Gateway to NUCALA services, which may include the following activities:

- 1) Communicating with my Healthcare Providers about my NUCALA prescription and medical condition;
- 2) Investigating and resolving my insurance coverage, coding, or reimbursement inquiry, or reviewing my eligibility for GSK’s patient assistance and co-pay assistance programs;
- 3) Contacting my insurer, other potential funding sources, and/or patient assistance programs on my behalf to determine if I am eligible for health insurance coverage or other funds;
- 4) Contacting me to offer (and, if I am interested, provide) optional educational services offered by healthcare professionals; and
- 5) Disclosing my information to third parties if required by law.

By signing this authorization, I **acknowledge** my understanding that:

- My Healthcare Providers will not and may not condition my treatment, payment for treatment, eligibility for or enrollment in benefits on whether I sign this Patient Authorization.
- Certain Healthcare Providers, such as Specialty Pharmacies, may receive payment from GSK for disclosing my information to GSK as permitted by this authorization.
- Once information about me is released to GSK based on this authorization, federal privacy laws may no longer protect my information and may not prevent GSK from further disclosing my information. However, I understand that GSK has agreed to use or disclose information received only for the purposes described in this authorization or as required by law.
- This authorization will remain in effect for two (2) years after I sign it (unless a shorter period is required by state law) or for as long as I participate in the Gateway to NUCALA Program, whichever is longer.
- I have the right to revoke this authorization at any time by mailing a signed written statement of my revocation to P.O. Box 5490, Louisville, KY 40255, but that such a revocation would end my eligibility to participate in the Gateway to NUCALA program. Revoking this authorization will prohibit further disclosures by my Healthcare Providers based on this authorization after the date written revocation is received but will not apply to the extent that they have already taken action in reliance on this authorization. After this authorization is revoked, I understand that information provided to GSK prior to the revocation may be disclosed within GSK to maintain records of my participation.
- I understand that I, as the patient or signer, have a right to receive a copy of this signed form.

The patient, or the patient’s authorized representative, **MUST** sign this form to receive Gateway to NUCALA services. If an authorized representative signs for the patient, please indicate relationship to the patient.

**This page intentionally left blank**